Steven T. Rosen, M.D.

800-826-4673
Steven Rosen
Play
Medical Oncologist And Hematologist; Provost And Chief Scientific Officer; Irell & Manella Cancer Center Director's Distinguished Chair; Morgan & Helen Chu Director's Chair Of The Beckman Research Institute
4.9 (144 RATINGS)
Clinical Expertise
Hematology-Oncology
Research Area
Leukemia
Lymphoma
Multiple Myeloma
Appointments
Director, Comprehensive Cancer Center
Director, Beckman Research Institute Of City Of Hope
Clinical Teams
Acute Myeloid Leukemia
Cutaneous Lymphoma Program
Hematology & Hematopoietic Cell Transplantation
Lymphoma

Steven T. Rosen, M.D., is provost and chief scientific officer for City of Hope and a member of City of Hope's Executive Team. He also is director of the comprehensive cancer center and Beckman Research Institute of City of Hope, and holds the Irell & Manella Cancer Center Director's Distinguished Chair and the Morgan & Helen Chu Director’s Chair of the Beckman Research Institute.

Dr. Rosen sets the scientific direction of City of Hope, shaping the research and educational vision for the biomedical research, treatment and education institution. Working closely and collaboratively with City of Hope's scientists, clinicians and administrative leaders, he develops strategies that contribute to the organization's mission.

As director of Beckman Research Institute, he works with faculty across the institution to help shape and direct the scientific vision for the institute while leading the vital basic and translational research that is fundamental to our strategic plan and mission. He focuses on opportunities for expanding and integrating our research initiatives; recruiting and leading talented scientists, helping our talented researchers achieve national and international recognition, and promoting our national standing as a premier scientific organization.

Prior to joining City of Hope, Dr. Rosen was the Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine at Northwestern University in Chicago. He served for 24 years as director of Northwestern's Robert H. Lurie Comprehensive Cancer Center. Under his leadership, the center received continuous National Cancer Institute (NCI) funding beginning in 1993 and built nationally recognized programs in laboratory sciences, clinical investigations, translational research and cancer prevention and control. The center attained comprehensive status in 1997.

Dr. Rosen has published more than 400 original reports, editorials, books and book chapters. His research has been funded by the NCI, American Cancer Society, The Leukemia & Lymphoma Society and Multiple Myeloma Research Foundation. Dr. Rosen also has served as an adviser for several of these organizations and on the external advisory boards of more than a dozen NCI-designated comprehensive cancer centers. He is the current editor-in-chief of the textbook series "Cancer Treatment & Research."

Recognized as one of the "Best Doctors in America," Dr. Rosen is a recipient of the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital and the Man of Distinction Award from the Israel Cancer Research Fund. He is also a member of the American Institute for Medical and Biological Engineering’s College of Fellows. Dr. Rosen earned his bachelor's degree and medical degree with distinction from Northwestern University, and is a member of the Alpha Omega Alpha Honor Society.

Location
Education & Experience
Degrees

  • 1976, M.D., Northwestern University Medical School, Chicago, IL

  • 1972, B.M., Honors Program, Northwestern University, Evanston, IL

Fellowship

  • 1979-1981, Fellowship in Hematology/Oncology, National Cancer Institute, Bethesda, MD

Residency

  • 1977-1979, Residency in Internal Medicine, Northwestern Memorial Hospital, Chicago, IL

Professional Experience

  • 2018-present, Morgan & Helen Director’s Chair of the Beckman Research Institute, City of Hope, Duarte, CA

  • 2014-present, Provost and Chief Scientific Officer, City of Hope, Duarte, CA

  • 2014-present, Director, Comprehensive Cancer Center and Beckman Research Institute, City of Hope, Duarte, CA

  • 2014-2020, Director, Irell & Manella Graduate School of Biological Sciences, City of Hope, Duarte, CA

  • 1989-2014, Director, The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  • 1989-2014, Director of Cancer Programs, Northwestern Memorial Hospital, Chicago, IL

  • 1989-2014, Genevieve Teuton Professor of Medicine, Feinberg School of Medicine at Northwestern University, Chicago, IL

  • 1981-2014, Attending Physician, Northwestern Memorial Hospital, Chicago, IL

  • 1982-1986 Assistant Professor, Department of Medicine, Northwestern Univ. Medical School, Chicago, IL

  • 1981-1987, Staff Physician, Division of Hematology/Oncology, Veterans Administration Lakeside Medical Center, Chicago, IL

  • 1981, Associate, Department of Medicine, Northwestern Univ. Medical School, Chicago, IL

Research
Laboratory
Dr. Rosen is a clinician and scientist with expertise in the diagnosis and treatment of blood cancers, particularly non-Hodgkin lymphoma, cutaneous lymphoma, chronic lymphocytic leukemia and multiple myeloma. He has been a pioneer in the use of biological therapies including:
 
  • monoclonal antibodies and recombinant toxins that can specifically target cancer cells
  • apoptosis inducers, proteasome inhibitors and metabolism inhibitors to promote cancer cell death
  • RNA based analogs and cell signaling regulators that can interfere with cancer growth processes
  • vaccines, interferons and cytokines that can trigger an immune response against cancer cells
  • angiogenesis inhibitors to prevent cancer from growing new blood vessels
  • transcriptional regulators and antisense compounds to activate or silence certain genes in cancer and normal cells
  • hormone therapies
     
He has conducted numerous clinical trials and is recognized as one of the leading figures in “bench to bedside” research by rapidly transforming scientific breakthroughs into promising therapies.
 
Active
 
1.    National Cancer Institute, (2018-2023) 2P30 CA033572-35, Cancer Center Support Grant, $1,970,050/year direct (PI: S. Rosen – 50% effort). (funding pending)
 
2.    National Cancer Institute, (2015-2020) R01 CA201496, Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia, $428,649/year direct (PI: S. Rosen - 10% effort)
 
3.    National Cancer Institute,  (2019-2024) R01 CA233922-01, Targeting p38 Gamma Signaling to Advance Cutaneous T Cell Lymphoma Therapy (PI: S. Rosen) –$3,459,245
 
4.    National Cancer Institute, (2017-2022) R01 CA212119, Targeting c-Myc and Proteasome Inhibitor Resistance in Multiple Myeloma. $404,591 (Co-Investigator: S. Rosen)
 
5.    Leukemia & Lymphoma Society, (2018-2021) 1527-18, Developing novel p38γ inhibitors for targeted therapy of cutaneous T cell lymphoma (CTCL)  (PI: S. Rosen)
 
6.    The Harvey L. Miller Family Foundation, (2016-2021), Jacki and Bruce Barron Cancer Research Scholars Program (PI: S. Rosen)
 
7.    Judy and Bernanrd Briskin Family Foundation, (2016-2018), Multyiple Myeloma Research Project (PI: S. Rosen)
      
8.    Conrad N. Hilton Foundation, (2016 -2021), AH#977655, Launch of a Comprehensive Cancer Prevention Initiative, $2,500,000
Lab Members
Ralf Buettner
Staff Scientist
 
Xu Hannon Zhang
Assistant Research Professor
Awards & Memberships
Awards

  • 2020, Pasadena Magazine, The Influential 50

  • 2019, Association of American Physicians

  • 2018, Marquis Who’s Who Albert Nelson Marquis Lifetime Achievement Award

  • 2018, American Institute for Medical and Biological Engineering’s College of Fellows

  • 2017, American Institute of Medical and Biological Engineering

  • 2017, American Society of Clinical Oncology Fellow

  • 2017, Los Angeles Business Journal Hospital Executive of the Year
    2016, Angel Award for Outstanding Medical Service in the Cancer Community (Immerman Angels)

  • 2015, Israel Cancer Research Fund Lifetime Achievement Award

Publications
  • Robert Chen, Alex Herrera, Jessie Hou, Lu Chen, Jun Wu, Yuming Guo, Timothy Synold, Vu Ngo, Sandrine Puverel, Matthew Mei, Leslie Popplewell, Stephen Forman, Larry Kwak, Steven Rosen, and Edward Newman.  Inhibition of MDRI overcomes resistnace to brentuximab vendotin in Hodgkin Lymphoma. Clinical Cancer Research, August 2019 (submitted).
  • Domenico Viola, Ada Dona, Marianna Martella, Emine Gulsen Gunes, Estelle Troadec, Enrico Caserta, Francesca Besi, Xiwei Wu, Sergio Branciamore, Tinisha McDonald , Lucy Ghoda, James F Sanchez, Chatchada Karanes, Myo Htut, Xiuli Wang, Ling Li, Nadia Carlesso, Michael Rosenzweig, Douglas Sborov, Aaron Miller, Steven J Forman, Paul Yazaki, Jonathan J Keats, John Shively, Steven T Rosen, Guido Marcucci, Amrita Krishnan and Flavia Pichiorri. Daratumumab mechanisms of action in myeloma patients highlight the role of CD38 as immune activator.  (submitted)
  • Xochiquetzal Martinez, Cosimo Di Raimondo, Farah Abdulla, Jasmine Zain, Steven Rosen, Christiane Querfeld.  Leukaemic Variants of Cutaneious T-Cell Lymphome : Erythrodermic Mycosis Fungoides and SÉZARY Syndrome.  Journal: Best Practice & Research Clinical Haematology (accepted)
  • Ralf Buettner, Corey Morales, Xiwei Wu, James F. Sanchez, Hongzhi Li, Laleh G. Meldstrom and Steven T. Rosen.  Leflunomide Synergizes with Gemcitabine in Grown Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting.  Molecular Therapy: Oncolytics Vol. 14, September 2019.  doi.org/10.1016/j.omto.2019.04.006.
  • Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, Zhang B, Nguyen DQ, Aldoss I, Ghoda L, Budde E, Pichiorri F, Rosen S, Foramn SJ, Marcucci G, Pullarkat V.  The Bcl-2 Inhibitor Venetoclax inhibits Nrf2 Antioxidant Pathway Activation induced by hypomethylating agents in AML.  Journal of Cellular Physiology 2019 Aug; 234(8):14040-14049. doi: 10.1002/jcp.28091.
  • Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, His ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients After Front Line Therapy from the COMPLETE Registry. Acta Haematologica 2019 Jul 17:1-11. doi: 10.1159/000500666.
  • Lu Yang, Anthony K.N. Chun, Kazuya Myashita, Chris Delaney, Xi Wang, Hongzhi Li, Wen-Han Chang, Sheela Pangeni Pokharel, Sandra Li, Kevin Yining Chen, Yanchun Guo, Mingli Li, Xiaobao Xu, Jinhui Wang, David Horne, Nagarajan Vaidehi, Yuan Chen, Jianjun Chen, Markus Müschen, Steven T. Rosen, Yadira Soto-Feliciano, Zhaohui Feng, Takayuki Hoshii, Scott A. Armstrong, Chun-Wei Chen. Saturating CRISPR gene body scan identifies sub-domain functional elements in proteins" (reference number: NBT-RA47887). (submitted to Nature Biotechnology) May 2019.
  • Dean Ho, Steven T. Rosen, Quake, Edward R.B. McCabe, Megan L. Frisk, wee Joo Chng, Edward Chow, Xianting Ding, Bruce D. Gelb, Geoffrey S. Ginsburg, Chih-Ming Ho, William Mobley, Garry  Nolan,  Patrick Tan, Yen Yun, Ali Zarrinpar.  Engineering Enabling Technologies for Personalized and Precision Medicine. (accepted)  
  • Buettner R, Nguyen LXT, Kumbar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST.  8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.  Journal of Cellular Physiology 2019 February 15. doi: 10.1002/jcp.28294.
  • Ralf Buettner, Corey Morales, Enrico Caserta, Estelle Troadec, Emine G. Gunes, Domenico Viola, Jihane Khalife, Hongzhi Li, Jonathan J. Keats, Austin Christofferson, Xiwei Wu, Timothy W. Synold, Joycelynne Palmer, James F. Sanchez, Aleander Pozhitkov, Nagarajan Vaidehi, Guido Marcucci, Amrita Krishnan, Michael a. Rosenzweig, Flavia Pichiorri and Steven T. Rosen.  Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.  Blood Advances 2019 3:1027-1032; doi:  https//doi.org/10.11.1182.2018027227
  • Chang L, Shen L, Zhou H, Gao J, Pan H, Zheng L, Armstrong B, Peng Y, Peng G, Zhou BP, Rosen ST, Shen B. ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response. Nucleic Acids Res. 2019 Jan 25;47(2):824-842. doi: 10.1093/nar/gky1199.
  • Atish, Mohanty, Natalie Sandoval, An Phan, Thang V. Nguyen, Robert W. Chen, Elizabeth Budde, Matthew Mei, Leslie Popplewell, Lan V. Pham, Larry W. Kwak, Dennis D. Weisenburger, Steven T. Rosen, Wing C. Chan, Markus Müschen and Vu N. Ngo.  Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.  Blood. 24 January 2019; Volume 133, Number 4.
  • Ndiya Ogba, PhD, Nicole M. Arwood, PharmD, Nancy L. Bartlett, MD, Mara Bloom, JD, Patrick Brown, MD, Christine Brown, PhD, Elizabeth Lihua Budde, MD, PhD, Robert Carlson, MD, Stephanie Farnia, MPH, Terry J. Fry, MD, Morgan Garber, MSW, Rebecca A. Gardner, MD, Lauren Gurschick, NP, Patricia Kropf, MD, Jeff J. Reitan, MA, Craig Sauter, MD, Bijal Shah, MD, Elizabeth J. Shpall, MD and Steven T Rosen, MD.  Chimeric Antigen Receptor T-Cell Therapy.  Journal of the National Comprehensive Cancer Network (JNCCN); Volume 16-Number 9-September 2018.
  • Li YJ, Du L, Aldana-Masangkay G, Wang X, Urak R, Forman SJ, Rosen ST, Chen Y.  Regulation of miR-34b/c-targeted gene expression program by SUMOylation.  Nucleic Acids Res. 2018 Aug 21;46(14):7108-7123. doi: 10.1093/nar/gky484.  PMID: 29893976. PMCID: PMC6101486.
    221.    Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, Satoskar AR, Hofmeister CC, Pichiorri F. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018 July 23;7(10):e1486948.
  • Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA.  Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.  PMID: 29954415. PMCID: PMC6022297.
  • Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P.  Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.  Biol Blood Marrow Transplant 2018 Mar;24(3): 514-520. doi: 10.1016/j.bbmt.2017.11.023.
  • Xu Hannah Zhang, Sangkil Nam, Jun Wu, Xuxiang Liu, Hongzhi Li, Timothy Mckeithan, Qiang Gong, Wing Chan, Hongwei Yin, Yate-Ching Yuan, Raju Pillai, David Horne, Yuan Chen, Steven Rosen.  Multi-kinase Inhibitor with Anti-p38y Activity in Cutaneous T cell Lymphoma. Journal of Investigative Dermatology. 2018, doi:10.1016/j.jid.2018.04.030
  • Christiane Querfeld, Samantha Leung, Patricia L. Myskowski, Shane A. Curran, Debra A. Goldman, Glen Heller, Xiwei Wu, Sung Hee Kil, Sneh Sharma, Kathleen J. Finn Steven Horowitz, Alison Moskowitz, Babak Mehrara, Steven T. Rosen, Allan C. Halpern, James W. Young.  Primary Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.  Cancer Immunology Research; 6(8) August 2018.
  • Martinez-Escala, M.E., Posligua, A.L., Wickless, H., Rutherford, A., Sable, K.A., Rubio-Gonzalez, B., Zhou, X.A., Kaplan, J.B., Pro, B., Choi, J., Querfeld, C., Rosen, S.T., & Guitart, J.  Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. Journal of the American Academy of Dermatology. 2018, Jun: 78(6); 1068-1076.
  • Kumar B, Kalvala A, Chu S, Rosen S, Forman SJ, Marcucci G, Chen CC, Pullarkat V.  Antileukemic Activity and Cellular Effects of the Antimalarial Agent Artesunate in Acute Myeloid Leukemia. Leuk Res. 2017 Aug;59:124-135. doi: 10.1016/j.Leukres.2017.05.007. Epub 2017 May 10.
  • Seymour JF, Ma S, Brander D, Choi M, Barrientos J, Davids MS, Anderson MA, Beaven A,  Rosen ST, Tam C,  Prine B,  Agarwal S,  Munasinghe W,  Zhu M,  Cerri E,  Verdugo M,  Kim SY, Humerickhouse R, Gordon G, Kipps T,  Roberts AW.  Venetoclax plus rituximab in relapsed or refractory chronic leukaemia: a phase 1b study.  Lancet Oncology.  2017 Feb;18(2):230-240.  doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.
  • Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin H, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN.  CCND1 mutations increase protein stability and promote stability and promote ibrutinib resistance in mantle cell lymphoma.  Oncotarget.  2016 Nov 8;7(45):73558-73572.  doi: 10.18632/oncotarget.12434.
  • Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.  A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.
  • Hsi E, Foss F, Horwitz S, Carson K, Pinter-Brown L, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm L, Acosta M, Collie A, Gruver A, Grzywacz B, Turakhia S, Shustov A, Advani R, Feldman T, Lechowicz M, Smith S, Lansigan F, Tulpule A, Craig M, Greer J, Kahl B, Leach J, Morganstein N, Casulo C, Park S.  Analysis of Peripheral T-Cell Lymphoma Diagnostic Work-Up in the United States. Clin Lymhoma Myeloma Leuk.  2017 Apr;17(4): 193-200. doi: 10.1016/j.clml.2016.10.001. Epub 2017 Jan 10.
  • Alex F. Herrera, Matthew Mei, Lawrence Low, Haesook T. Kim, Gabriel K. Griffin, Joo Y Song, Reid W. Merryman, Victorial Bedell, Christine Pak, Heather Sun, Tanya Paris, Tracey Stiller, Jennifer R. Brown, Lihua E. Budde, Wing C. Chan, Robert Chen, Matthew S. Davids, Arnold S. Freedman, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Ann S. LaCasce, Joyce Murate-Collins, Auayporn P. Nademanee, Joycelynne M. Palmer, German A. Phihan, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Aliyah R. Sohani, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, David M. Weistock, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Scott J. Rodig, Amrita Krishnan, and Philippe Armand. Relapsed or Refractory Double-Expressor and double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplant. Journal of Clinical Oncology. Volume 35, Number 1, January 1, 2017.
  • Rubio-Gonzalez B, Zain J, Rosen ST, Querfeld C. Clinical manifestations and pathogenesis of cutaneous lymphomas; current status and future directions, British Journal of Haematology, Volume 176, Issue 1, 26 October 2016.
  • Rubio-Gonzalez B, Zain J, Garcia L, Rosen ST, Querfeld C.  Cutaneous gamma-delta T-cell lymphoma – successfully treated with brentuximab vedotin. JAMA Dermatol (online Sept 21, 2016) 152:12, 2016.
  • Virmani P, Jawed S, Myskowski P, Horwitz S, Lucas A, Moskowitz A, Pulitzer M, Zain J, Rosen ST, Querfeld C.  Long-term followup and management of small/medium-sized CD4+ T cell lymphoma and CD8+ lymphoid proliferation of acral sites: a multi-center experience.  Int J Dermatology. 2016 Jul 1. doi: 10.1111/ijd. 13340. [Epub ahead of print]
  • Nardi E, Wolfson J, Rosen ST, Diasio R, Gerson S, Parker B, Alvarnas J, Levine H, Fong Y, Weisenburger D, Fitzgerald C, Egang M, Stranford S, Carlson R, Benz Jr E. Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers.  J Natl Compr Canc Netw. 2016 Jul;14(7):837-47.
  • Martinez-Escala, M.E., Kuzel, T.M., Kaplan, J.B., Petrich, A., Nardone, B., Rosen, S.T., & Guitart, J. Durable Responses With Maintenance Dose-Sparing Regimens of Romideepsin in Cutaneious T-Cell Lymphoma.  JAMA Oncology. 2016, June: 2(6); 790-793.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
5.0
Know important info medical history
5.0
Show respect for what you say
5.0
Rate provider 0-10
5.0
Recommend this provider office
5.0
Provider listen carefully to you
4.9
Spend enough time with you
4.9
Provider explain in way you understand
Reviews
02/07/23
I have and always continue to refer people to city of hope- we need more providers like you - Verified patient
02/07/23
You are the only provider I will ever refer people to - Verified patient
12/01/22
If I ever have a repeat of cancer Dr Rosen Is the only doctor I would want to take care of my problem. - Verified patient
10/05/22
Very satisfied - Verified patient
09/12/22
Dr Rosen is the VERY BEST! - Verified patient